Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the effects of traditional Chinese herbal products on hair loss alopecia and gray hair canities in adults aged 18 to 60 years. This 6-month randomized, double-blind, placebo-controlled trial will enroll 152 participants, including some with gray hair, to study changes in hair count, density, and color. The trial aims to better understand how oral capsules and topical hair tonics may impact hair health. Participants will be randomly assigned to one of four groups, each receiving a combination of oral capsules and hair tonic or placebos for 24 weeks. The groups include VitaGreen Capsule A plus VitaGreen Tonic, VitaGreen Capsule B plus VitaGreen Tonic, Capsule Placebo plus VitaGreen Tonic, and Capsule Placebo plus Tonic Placebo. Treatments will be used as directed throughout the 24-week period. During the study, participants will attend three in-person visits at baseline, week 12, and week 24. Hair-related assessments include hair shedding counts, local hair counts, hair density, and photographic scoring of hair changes. A subset of participants with gray hair will have additional evaluations of hair color changes. Blood tests, urinalysis, and safety monitoring for adverse events will also be conducted. All clinical data will be collected for analysis, with the total participation lasting about six months.
Actively Recruiting
Researchers are studying the safety, tolerability, and effectiveness of elecoglipron alone or combined with dapagliflozin compared to placebo in adults with type 2 diabetes mellitus T2DM who are not well controlled with lifestyle changes or other glucose-lowering medications. This Phase III trial aims to better understand how these treatments impact blood sugar control and other health measures. Participants will be randomly assigned to one of four groups elecoglipron at dose level 1 with dapagliflozin placebo, elecoglipron at dose level 2 with dapagliflozin placebo, elecoglipron at one of the studied doses combined with dapagliflozin, or matching placebos for both drugs. All medications are taken orally once daily. The study lasts 40 weeks, during which participants receive their assigned treatment and are monitored. During the study, participants will undergo regular assessments including measurements of blood sugar control HbA1c, body weight, and blood pressure from baseline to Week 40. Researchers will also track the achievement of specific blood sugar targets, weight loss percentages, and the time before needing additional diabetes medication. Safety and tolerability will be monitored throughout the treatment period. The total participation duration is approximately 40 weeks.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of plonmarlimab in adults with acute gouty arthritis. This phase II, multicenter, randomized, double-blind, double-dummy, active-controlled study aims to compare plonmarlimab against an active comparator to understand its effects on pain reduction as measured by the Visual Analogue Scale VAS within 72 hours after dosing. An interim analysis after the first 60 participants will guide potential adjustments to sample size and treatment group selection. Participants are randomly assigned to one of three groups plonmarlimab 3 mgkg as a single intravenous infusion, plonmarlimab 6 mgkg as a single intravenous infusion, or compound betamethasone 7 mg as a single intramuscular injection. The study includes a double-dummy design with placebos matching both active treatments. The primary focus is on the initial single dose administration, with no further dosing detailed. Participants will be assessed for pain intensity using the VAS score at 72 hours after the initial dose. The study collects data on treatment safety, tolerability, pharmacokinetics, and immunogenicity. The trial duration and visit schedule beyond the primary outcome are not specified, but participants are monitored closely during the initial treatment period to evaluate study endpoints and safety.
Actively Recruiting
Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.
Actively Recruiting
Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.
Actively Recruiting
Researchers are studying the safety and effectiveness of early use of tirofiban in patients who have acute ischemic stroke and are treated with tenecteplase. This study is exploring whether adding tirofiban soon after tenecteplase can reduce the risk of blood clot re-blockage in the brain, which happens in some patients after initial treatment. The study is a phase 3 trial aiming to improve stroke outcomes by preventing this reocclusion. Participants first receive tenecteplase intravenously for stroke treatment. Those who meet the study criteria are then randomly assigned to receive either tirofiban or a placebo. Tirofiban or placebo is given intravenously starting as soon as possible after randomization, initially as a higher dose for 30 minutes, followed by a continuous lower dose infusion for nearly 48 hours. After 24 hours, patients receive aspirin andor clopidogrel or their placebos, then after 44 hours, antiplatelet therapy with aspirin andor clopidogrel continues until the 90-day follow-up. During the study, participants undergo assessments including neurological exams and monitoring for bleeding or other adverse events. The main outcome measured is excellent functional recovery 90 days after randomization. Other outcomes include disability levels, neurological improvement, quality of life, bleeding events, and mortality. Safety and serious adverse events are tracked through the 90-day period to evaluate treatment effects and risks.
Actively Recruiting
Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.
Actively Recruiting
Researchers are studying the use of Tenecteplase TNK combined with Butylphthalide NBP in patients who have experienced mild disabling acute ischemic stroke AIS. This large, randomized, double-blind trial compares the effects of TNK plus NBP versus TNK alone to see if the combination improves neurological function and recovery. Patients eligible for the study are adults aged 18 to 80 years who have had a stroke within 4.5 hours and meet specific neurological severity criteria. Participants are randomly assigned to one of two groups. The combination group receives a single intravenous dose of TNK followed by intravenous NBP twice daily for 7 days, then oral NBP capsules three times daily until Day 14. The control group receives the same TNK dose followed by a matching placebo infusion and capsules on the same schedule. Treatments are administered during hospitalization and continue after discharge if needed. Throughout the 90-day study period, participants undergo assessments including stroke severity scores, functional recovery measured by the Modified Rankin Scale, quality of life surveys, and imaging to evaluate brain tissue salvage. Safety monitoring tracks adverse events like bleeding or vascular complications. The main outcome is the proportion of patients achieving minimal disability by 90 days, with additional evaluations of neurological improvement and stroke recurrence.
Actively Recruiting
Researchers are studying the effects of lunsekimig, given as a subcutaneous injection, in adults aged 40 to 80 years with chronic obstructive pulmonary disease COPD that is not well controlled and characterized by an eosinophilic phenotype. This Phase 2bPhase 3, randomized, double-blind, placebo-controlled study compares two dosing regimens of lunsekimig against placebo to evaluate its efficacy, safety, and tolerability over a prolonged period. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a matching placebo. They will receive subcutaneous injections during a treatment period of about 48 weeks. The study includes a screening phase lasting up to 4 weeks before treatment, followed by an 8-week follow-up after the intervention, totaling up to 60 weeks of participation. During the trial, participants will undergo regular assessments including lung function tests, symptom questionnaires like the Chronic Airways Assessment Test CAAT, and monitoring of exacerbations and adverse events. Researchers will measure the rate of moderate to severe COPD exacerbations as the primary outcome. Safety labs, antibody testing, and drug concentration monitoring will also occur. Participants will be monitored throughout the study duration, including follow-up after treatment ends.
1-10 of 18
1